Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of CD4+ CD25- T cells in coculture with regulatory B cells expressing granzyme B (GZMB+Bregs) or total B cells

ABSTRACT: Gene expression profile of CD4+ CD25- T cells in coculture with regulatory B cells expressing granzyme B (GZMB+Bregs) or total B cells

PROVIDER: PRJNA934570 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23332748_1.fastq.gz	Fastqsanger.gz
	SRR23332748_2.fastq.gz	Fastqsanger.gz
	SRR23332749_1.fastq.gz	Fastqsanger.gz
	SRR23332749_2.fastq.gz	Fastqsanger.gz
	SRR23332750_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Regulatory B cells expressing granzyme B (GZMB+Bregs)

Project description:Regulatory B cells expressing granzyme B (GZMB+Bregs)

| PRJNA931282 | ENA

Gene expression profile at single cell level of in vitro induced regulatory B cells expressing granzyme B (GZMB+Bregs) and non-Bregs from healthy donors and kidney transplant recipients.

Project description:Regulatory B cells are considered as a very heterogenous population of different origins and functions. We used single cell RNA sequencing (scRNA-seq) to analyze the regulatory B cells expressing granzyme B (GZMB+Bregs).

2023-08-23 | GSE224460 | GEO

Gene expression profile of CD4+ CD25- T cells in coculture with regulatory B cells expressing granzyme B (GZMB+Bregs) or total B cells

Project description:Regulatory B cells are considered as a very heterogenous population of different origin and functions. Here, we show that Notably, Bregs induced a strong inhibition of T cell genes associated to proliferation, activation, inflammation and apoptosis compared to total B cells. We identified and validated 5 receptor/ligand interactions between Bregs and T cells.

2023-08-23 | GSE224456 | GEO

Gene expression profile at single cell level of in vitro induced regulatory B cells expressing granzyme B (GZMB+Bregs) and non-Bregs from healthy donors and kidney transplant recipients.

Project description:Gene expression profile at single cell level of in vitro induced regulatory B cells expressing granzyme B (GZMB+Bregs) and non-Bregs from healthy donors and kidney transplant recipients.

| PRJNA934568 | ENA

Profiling of Granzyme B Secreting B cells

Project description:B cells with regulatory functions have been described both in immune homeostasis in healthy volunteers and in different pathological conditions. Whereas Il-10 secreting B cells represent the main subset described, recently, a subset of B cells secreting granzyme B (GZMB+) was evidenced in a growing numbers of immunological contexts, autoimmunity, chronic infections and neoplasias. Until now, no phenotype has been evidenced for these GZMB+ B cells and their regulatory functions as well are still to clarify.

2020-09-27 | GSE125901 | GEO

A novel and divergent role of granzyme A and B in resistance to helminth infection

Project description:Granzyme (gzm) A and B, proteases of NK cells and T killer cells, mediate cell death, but also cleave extracellular matrices, inactivate intracellular pathogens and induce cytokines. Moreover, macrophages, T helper 2 cells, regulatory T cells, mast cells and B cells can express gzms. We recently reported gzm induction in human filarial infection. Here we show that in rodent filarial infection with Litomosoides sigmodontis worm loads were significantly reduced in gzmAxB and gzmB knock out (ko) mice, but enhanced in gzmA ko compared to wildtype (wt) mice. GzmA/B deficiency was associated with a defense-promoting Th2 cytokine and antibody shift and enhanced early inflammation gene expression, whereas gzmA deficiency was linked with alternatively activated macrophages and reduced inflammation. This suggests a novel and divergent role for gzms in helminth infection with gzmA contributing to resistance and gzmB promoting susceptibility. Keywords: knock out vs wild type

2011-07-29 | GSE17544 | GEO

Profiling of Granzyme B Secreting B cells

Project description:Profiling of Granzyme B Secreting B cells

| PRJNA517914 | ENA

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death

Project description:The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. While not observed in mouse ILC2s, we have found that human ILC2s secrete granzyme B (GZMB) and directly lyse tumor cells by inducing pyroptosis and/or apoptosis, which is governed by a DNAM-1CD112/CD155 interaction that inactivates FOXO1. Over time, the high surface density expression of CD155 in AML impairs expression of DNAM-1 and GZMB, thus allowing for immune evasion. We describe a reliable platform capable of up to 2,000-fold expansion of human ILC2s within 4 weeks, whose molecular and cellular ILC2 profile has been validated by single-cell RNA sequencing. In both AML and solid tumor models, exogenously administered expanded human ILC2s show significant antitumor effects in vivo. Collectively, we demonstrate previously unreported properties of human ILC2s and identify this innate immune cell subset as a new member of the cytolytic immune effector cell family.

2024-01-01 | GSE247206 | GEO

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death

Project description:The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. While not observed in mouse ILC2s, we have found that human ILC2s secrete granzyme B (GZMB) and directly lyse tumor cells by inducing pyroptosis and/or apoptosis, which is governed by a DNAM-1-CD112/CD155 interaction that inactivates FOXO1. Over time, the high surface density expression of CD155 in AML impairs expression of DNAM-1 and GZMB, thus allowing for immune evasion. We describe a reliable platform capable of up to 2,000-fold expansion of human ILC2s within 4 weeks, whose molecular and cellular ILC2 profile has been validated by single-cell RNA sequencing. In both AML and solid tumor models, exogenously administered expanded human ILC2s show significant antitumor effects in vivo. Collectively, we demonstrate previously unreported properties of human ILC2s and identify this innate immune cell subset as a new member of the cytolytic immune effector cell family.

2024-01-01 | GSE247205 | GEO

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death

2024-01-01 | GSE247207 | GEO